Posted by Michael Wonder on 30 Oct 2023
Sellas Life Sciences receives fast track designation from FDA for SLS009 for treatment of relapsed/refractory peripheral T-cell lymphomas
30 October 2023 - LS009 demonstrated promising efficacy in Phase 1 Study with 36.4% clinical response in relapsed/refractory peripheral T-cell lymphomas; overall response rate in relapsed/refractory peripheral T-cell lymphoma patients with standard care is 25.8%.
Sellas Life Sciences Group today announced that the US FDA has granted fast track designation to SLS009, its novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory peripheral T-cell lymphomas.
